Browse

Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models

Cited 59 time in Web of Science Cited 64 time in Scopus
Authors
Joo, Yuyoung; Kim, Hye-Sun; Woo, Ran-Sook; Park, Cheol Hyoung; Shin, Ki-Young; Lee, Jean-Pyo; Chang, Keun-A; Kim, Seonghan; Suh, Yoo-Hun
Issue Date
2005-10-15
Publisher
American Society for Pharmacology and Experimental Therapeutics (ASPET)
Citation
Mol Pharmacol. 2006 Jan;69(1):76-84. Epub 2005 Oct 13.
Keywords
Alzheimer Disease/*physiopathologyAmyloid beta-Protein/metabolismAnimalsAnti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic useCaspase 3Caspases/metabolismCell Differentiation/drug effectsCognition Disorders/*drug therapyEnzyme ActivationMaleMefenamic Acid/*pharmacology/therapeutic useMembrane Potentials/drug effectsMitochondria/drug effectsNerve Growth Factor/pharmacologyNeuroprotective Agents/*pharmacology/therapeutic usePC12 CellsPeptide Fragments/metabolismRatsRats, WistarReactive Oxygen Species/metabolismTransfection
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory, analgesic, and antipyretic activities and suppress prostaglandin synthesis by inhibiting cyclooxygenase, an enzyme that catalyzes the formation of prostaglandin precursors from arachidonic acid. Epidemiological observations indicate that the long-term treatment of patients suffering from rheumatoid arthritis with NSAIDs results in reduced risk and delayed onset of Alzheimer's disease. In this study, we investigated the therapeutic potential for Alzheimer's disease of mefenamic acid, a commonly used NSAID that is a cyclooxygenase-1 and 2 inhibitor with only moderate anti-inflammatory properties. We found that mefenamic acid attenuates the neurotoxicities induced by amyloid beta peptide (Abeta)(1-42) treatment and the expression of a Swedish double mutation (KM595/596NL) of amyloid precursor protein (Swe-APP) or the C-terminal fragments of APP (APP-CTs) in neuronal cells. We also show that mefenamic acid decreases the production of the free radical nitric oxide and reduces cytochrome c release from mitochondria induced by Abeta(1-42), Swe-APP, or APP-CTs in neuronal cells. In addition, mefenamic acid up-regulates expression of the antiapoptotic protein Bcl-X(L). Moreover, our study demonstrates for the first time that mefenamic acid improves learning and memory impairment in an Abeta(1-42)-infused Alzheimer's disease rat model. Taking these in vitro and in vivo results together, our study suggests that mefenamic acid could be used as a therapeutic agent in Alzheimer's disease.
ISSN
0026-895X (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16223958

http://hdl.handle.net/10371/29734
DOI
https://doi.org/10.1124/mol.105.015206
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pharmacology (약리학전공)Journal Papers (저널논문_약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse